Ordering
Available Variants10 mg
CHA.78458-10mg
Price
€103.20
Available – Dispatch in 14 days
25 mg
CHA.78458-25mg
Price
€214.40
Available – Dispatch in 14 days
100 mg
CHA.78458-100mg
Price
€604.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.78458-10mg | €103.20 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.78458-25mg | €214.40 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
100 mg | CHA.78458-100mg | €604.00 |
>98%, solid
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C13H10N2O4 |
|---|---|
| CAS Number | 841-67-8 |
| Molecular Weight | 258.23 |
| NACRES | NA.77 |
| PubChem Substance ID | 24899969 |
| UNSPSC Code | 12352207 |
| MDL number | MFCD00210219 |
| Assay | >98% |
| Form | solid |
Safety Information Handling visibility
| pictograms |
GHS08
GHS07
  GHS08,GHS07
|
|---|---|
| signalword | Danger |
| hcodes | H302,H360 |
| pcodes | P201 - P301 + P312 + P330 - P308 + P313 |
| Hazard Classifications | Acute Tox. 4 Oral - Repr. 1B |
| Storage Class | 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| wgk | WGK 3 |
| ppe | Eyeshields, Gloves, type P3 (EN 143) respirator cartridges |
Technical Overview & Applications Use-case context
(−)-Thalidomide, with the CAS number 841-67-8, is a single enantiomer of the racemic compound thalidomide, which has been utilized in the treatment of various medical conditions. Initially introduced as a sedative, its use was later discontinued due to severe teratogenic effects. However, research has led to its re-emergence as a therapeutic agent, particularly in the management of multiple myeloma and erythema nodosum leprosum. The mechanism of action of (−)-thalidomide involves the inhibition of tumor necrosis factor-alpha production, as well as the modulation of immune responses. Its enantiomeric purity is crucial, as the other enantiomer has been associated with the aforementioned adverse effects. As such, the development of (−)-thalidomide has provided a safer alternative for patients, with ongoing research aimed at further elucidating its therapeutic potential and optimizing its clinical application.
